Barinthus Biotherapeutics (BRNS) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

BRNS Barinthus Biotherapeutics

Watchlist

1.025
-0.020-1.91%

Trading Dec 4 13:49 ET

41.23MMarket Cap-687P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Barinthus Biotherapeutics Plc (NASDAQ:BRNS) Looks Inexpensive After Falling 35% But Perhaps Not Attractive Enough
Simply Wall StNov 26 06:10 ET
Barinthus Biotherapeutics Announces Geoffrey Lynn, M.D., Ph.D. as New Chief Scientific Officer
Quiver QuantitativeNov 25 16:13 ET
Press Release: Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
Dow JonesNov 25 16:01 ET
European Equities Traded in the US as American Depositary Receipts Rising Monday
MT NewswiresNov 25 11:13 ET
Promising Clinical Trials and Potential Functional Cure Drive Buy Rating for Barinthus Biotherapeutics
TipRanksNov 18 12:25 ET · Ratings
ADRs End Lower; Barinthus Biotherapeutics PLC Declines 30%
Dow JonesNov 15 16:31 ET

Comments

Stock_Drift

Nov 15 13:00

$Barinthus Biotherapeutics (BRNS.US)$

Jaguar8

Nov 15 10:03

NEWS

$Barinthus Biotherapeutics (BRNS.US)$
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Arbutus Biopharma and Barinthus Bio announced new preliminary data from Phase 2a IM-PROVE II trial showing enhanced results when combining imdusiran, VTP-300, and low-dose nivolumab in treating chronic hepatitis B virus. 23% of participants receiving this combination achieved HBsAg l...

Jaguar8

Oct 31 07:22

NEWS

$Barinthus Biotherapeutics (BRNS.US)$
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
Barinthus Biotherapeutics (NASDAQ: BRNS) announced that updated clinical data from its chronic hepatitis B program will be presented at The Liver Meeting® 2024 in San Diego. The late-breaking presentation will focus on VTP-300 combined with low-dose nivolumab and its association with HBsAg loss in specific chronic hepatitis B patien...

Trytosaveabit

Oct 21 18:10

Watching for upcoming data release!

$Barinthus Biotherapeutics (BRNS.US)$ •In the fourth quarter of 2024, the Company expects to:
◦VTP-300 (HBV):
▪Announce updated interim data from HBV003, our Phase 2b trial evaluating additional dosing of VTP-300 and timing of PD-1 inhibition, in people with CHB on NUC therapy.
▪Announce updated interim data from the Phase 2a AB-729-202 clinical trial evaluating the combination of VTP-300 and Arbutus’ imdusiran, in people with CHB on NUC therapy.

Jaguar8

Oct 1 07:07

NEWS

$Barinthus Biotherapeutics (BRNS.US)$
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
• Investigational immunotherapy, VTP-300, is being evaluated as part of a potential functional cure regimen for chronic Hepatitis B.
• Interim data update for HBV003 anticipated in Q4 2024.
• Data update for PCA001 anticipated in H1 2025.
OXFORD, United Kingdom, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Barinthus B...

Trending US Stocks

Symbol Mini Chart % Chg

Bitdeer Technologies

BTDR

+11.49%

NEPTUNE DIGITAL ASSETS CORP

Unlock the Full List